Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NasVax Ltd.

Latest From NasVax Ltd.

2011 Scrip 100: All to play for as new technologies shake up the vaccines market

New antigen types, novel delivery systems and a shift away from the low-hanging fruit towards more problematic conditions point to healthy prospects in the vaccines space, writes Dr Peter Charlish.

Infectious Diseases Cancer

Market Insight - Influenza, a persistent threat

Swine flu has continued to steal the headlines ever since its appearance in Mexico earlier this year. What can we learn from past influenza outbreaks and how safe should we feel, asks Jon Stephens

Gastrointestinal Gynecology & Urology

GSK granted option on pneumococcal vaccine proteins

The Israeli start-up Protea Vaccine Technologies has entered a collaboration and option agreement that grants GlaxoSmithKline Biologicals the option to obtain an exclusive licence to a set of Protea’s conserved pneumococcal proteins for the development and commercialisation of a universal protein-based Streptococcus pneumoniae vaccine. Protea is affiliated with another Israeli vaccine firm NasVax.

NasVax Ltd.

NasVax Ltd.'s VaxiSome, a novel adjuvant/delivery system for enhacing the activity of existing vaccines, consists of lipid assemblies comprising an innovative, proprietary family of positively charged polycationic lipids. The technology generates strong adjuvant activity, with the potential for intranasal, intramuscular, or subcutaneous administration. This platform can also be applied to boost the bioactivity of various immunomodulators, such as a broad spectrum of well-established adjuvants and cytokines.
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
    • Liposomes
  • Pharmaceuticals
    • Drug Delivery
      • Nasal
    • Vaccines
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Middle East
      • Israel
  • Parent & Subsidiaries
  • NasVax Ltd.
  • Senior Management
  • Erez Chimovits, CEO
  • Contact Info
  • NasVax Ltd.
    Phone: (972) 8-9396577
    18 Einstein St., Kiryat Weizmann
    Science Park
    Nes-Zionna , 74140